Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182862-100μg
|
100μg |
10
|
$89.90
|
|
|
Ab182862-1mg
|
1mg |
4
|
$419.90
|
|
|
Ab182862-5mg
|
5mg |
1
|
$1,089.90
|
|
|
Ab182862-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,749.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Crovalimab (anti-Complement C5) - Primary antibody, specific to C5, Human IgG1, INHIBITOR of Complement C5 inhibitor |
|---|---|
| Synonyms | Anaphylatoxin C5a analog antibody | C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody | C5 antibody | C5a anaphylatoxin antibody | C5a antibody | C5b antibody | CO5_HUMAN antibody | Complement C5 alpha'' chain antibody | Complemen |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | C5 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Complement C5 inhibitor |
| Product Description |
Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab (anti-Complement C5) can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab (anti-Complement C5) inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab (anti-Complement C5) has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.4 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 190.6 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1917321-26-6 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Crovalimab (anti-Complement C5) (Ab182862) - ELISA
Immobilized Human Complement C5 Protein at 2.0 μg/mL can bind Crovalimab (anti-Complement C5) (Ab182862) with the EC50 of 9.58 ng/mL.
Crovalimab (anti-Complement C5) (Ab182862) - SEC
The purity of Crovalimab (anti-Complement C5) (Ab182862) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 19, 2024 | Ab182862 | |
| Certificate of Analysis | Jun 19, 2024 | Ab182862 | |
| Certificate of Analysis | Jun 19, 2024 | Ab182862 |
Starting at $109.90
Starting at $89.90
Starting at $89.90
Starting at $109.90
Starting at $99.90